Skip to content

Study · Randomized controlled trial · 1999

2 results

Nafarelin acetate for pituitary suppressions in in-vitro fertilisation cycles--a Singaporean experience.

Loh SK, Leong NK

Singapore medical journal1 Dec 1999

PMID10709427 (opens in a new tab)PepBankPUB-10709427
Publisher pageAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

2 results from studies that gave the peptide. 2 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In IVF cycles, nafarelin and leuprolide did not differ significantly in time to pituitary suppression, total hMG dosage, or embryos produced or frozen.

    In plain wordsNafarelin and leuprolide did not differ significantly in suppression time, hMG dosage, or embryos produced or frozen.

    Peptide
    Nafarelin
    Outcome
    No significant changePituitary suppression, hMG dosage, and embryo outcomes
    Study

    n: not reported in source

    Comparator
    Leuprolide
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    800 micrograms/d · intranasalAs given in this study (human).

    Source sentences

    Summary
    There were no significant differences between LA and NA in terms of the mean duration of agonist to reach pituitary suppression, total hMG dosage, number of embryos produced or frozen and the clinical pregnancy rate (LA = 21.4% and NA = 16.3% per cycle).
    2 context sentences
    Summary · context
    The aim of this prospective clinical trial was to determine if intranasal nafarelin acetate (NA) is as effective as leuprolide (LA), our standard GnRHa, in IVF cycles.
    Summary · context
    Midluteal GnRHa administration (LA = 0.5 mg/d; NA = 800 micrograms/d) was used with a standardised hMG ovarian stimulation protocol for all 88 consecutive cycles, randomised at recruitment.
  2. 02HumanRandomized controlled trialEfficacy outcome

    Clinical pregnancy rates were 16.3% with nafarelin versus 21.4% with leuprolide per IVF cycle, without a significant difference.

    In plain wordsPregnancy rates were numerically lower with nafarelin than leuprolide, without a significant difference.

    Peptide
    Nafarelin
    Outcome
    DecreaseClinical pregnancy rate per cycle
    Study

    n: not reported in source

    Comparator
    Leuprolide
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    800 micrograms/d · intranasalAs given in this study (human).

    Measurements

    Clinical pregnancy rate
    16.3%
    nafarelin per cycle
    Clinical pregnancy rate
    21.4%
    leuprolide per cycle

    Source sentences

    Summary
    There were no significant differences between LA and NA in terms of the mean duration of agonist to reach pituitary suppression, total hMG dosage, number of embryos produced or frozen and the clinical pregnancy rate (LA = 21.4% and NA = 16.3% per cycle).
    2 context sentences
    Summary · context
    The aim of this prospective clinical trial was to determine if intranasal nafarelin acetate (NA) is as effective as leuprolide (LA), our standard GnRHa, in IVF cycles.
    Summary · context
    Midluteal GnRHa administration (LA = 0.5 mg/d; NA = 800 micrograms/d) was used with a standardised hMG ovarian stimulation protocol for all 88 consecutive cycles, randomised at recruitment.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:36 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.